In 2004, the Nobel Prize in Chemistry was awarded to Israeli scientists Aaron Sichanova, Afram Hershko and American scientist Irwin Ross for their discovery of ubiquitin-regulated protein degradation. Protein degradation is ratedRead More…
Recently, Pfizer and Arvinas jointly announced that they have reached an agreement to co-develop and promote the Protein Degrader protein degrader ARV-471. Arvinas will receive $650 million in upfront payments and potentiallyRead More…
Over the past decade, major changes have taken place in the field of drug targets. Although the traditional target is still the main direction, the R&D trend is gradually shifting from traditionalRead More…
Advantages of Protein Degrader technology Through Protein Degrader technology, it is possible to develop drugs against undruggable or difficult-to-drug targets of traditional inhibitors. The Protein Degrader does not rely on theRead More…
On December 14, 2020, Arvinas, a pioneer of Protein Degrader, announced the results of phase I clinical trials of new Protein Degrader drugs ARV-471 and ARV-110, of which ARV-471 showed outstanding efficacyRead More…
On January 26th, the application for the clinical trial of HSK29116 powder declared by Sichuan Haisco Pharmaceutical Co., Ltd. was accepted by the State Food and Drug Administration. HSK29116 is an oralRead More…
Protein Degrader is a novel technique that induces targeted protein degradation by the ubiquitin-proteasome system (UPS). Different from the traditional occupation-driven pharmacological principles, event-driven Protein Degrader technology has many advantages, such asRead More…
Over the past decade, major changes have taken place in the field of drug targets. Although traditional targets (such as kinases and G-protein-coupled receptors) are still the main stream, the focus isRead More…
On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…
Protein Degrader, of which the full name is proteolysis-targeting chimera, looks like a dumbbell and mainly consists of a linker, a ligand of interest protein, and a ligand recruiting E3 ubiquitin ligase.Read More…